Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03333187 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 2024 to Oct 7, 2024
    • Study completion date: Oct 2025 to Oct 7, 2025
    v5
  2. Primary completion date: Mar 2021 to Oct 2024v4 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 155 to confirmed 87
    • Study sites: 17 to 14
    • Study completion date: Jun 2024 to Oct 2025
  3. Primary completion date: Dec 20, 2019 to Mar 2021
    • Study sites: 18 to 17
    • Study completion date: Mar 20, 2023 to Jun 2024
    v3
  4. Study sites: 19 to 18
    • Interventions: Allogeneic stem cell transplantation (Biological), Ruxolitinib continuous therapy (Drug) to Allogeneic stem cell transplantation (Procedure), Ruxolitinib continuous therapy (Drug)
    • Secondary endpoints revised (20)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
Trial Details
NCT Number NCT03333187
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Collaborators: Novartis, Clinical Trial Center North (CTC North GmbH & Co. KG)
Conditions
(from sponsor)		 Bone Marrow Fibrosis
Related terms Myeloproliferative Disorders, Primary Myelofibrosis
Enrollment 87 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov